Ritlecitinib 100 mg

DRUG4 trials

Sponsors

Pfizer

Conditions

Alopecia AreataChronic Spontaneous UrticariaVitiligo

Phase 2

A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.

RecruitingNCT07219615

PfizerChronic Spontaneous Urticaria

Start: 2025-10-30End: 2027-04-23Target: 200Updated: 2026-06-17

Phase 3

A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo

Active, not recruitingNCT06163326

Start: 2024-01-19End: 2027-03-31Updated: 2026-08-26

A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata

RecruitingNCT06873945

PfizerAlopecia Areata

Start: 2025-04-01End: 2028-03-19Target: 674Updated: 2026-09-18

A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata

RecruitingNCT07733765

PfizerAlopecia Areata

Start: 2026-07-30End: 2028-04-26Target: 336Updated: 2026-09-10

Related Papers

Description of the Tranquillo Phase 3 Clinical Trial Designs/Study Protocols to Assess Ritlecitinib in Adults and Adolescents with Nonsegmental Vitiligo.

2026-05-22

Description of the 3 Tranquillo Phase 3 clinical program study designs to assess ritlecitinib treatment in adults and adolescents with nonsegmental vitiligo

SKIN The Journal of Cutaneous Medicine2025-11-10

Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata.

2025-10-14